Ventyx Biosciences, Inc. (VTYX) has disclosed a new risk, in the Supply Chain category. Ventyx Biosciences, Inc. is significantly exposed to ...

Tyra Biosciences' TYRA-300 shows promise as an FGFR3 inhibitor with fewer side effects, but mixed market reactions spotlight ...

HC Wainwright upgraded shares of Arcus Biosciences (NYSE:RCUS – Free Report) from a neutral rating to a buy rating in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm ...

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

Pacira BioSciences bought the remaining 81% equity stake of GQ Bio Therapeutics, adding a platform expected to help development of treatments for musculoskeletal pain.

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the company, ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) received a Refusal to File (RTF) letter from the U.S. Food and Drug ...

Cytek will host a conference call to discuss its fourth quarter and year end 2024 financial results on Thursday, February 27, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the ...

At this time, I would like to welcome everyone to Harmony Biosciences fourth quarter and full-year 2024 financial results ...

Araceli Biosciences secured $2.5 million from a lead investor for an $8 million round, the latest move from the startup that ...

Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 ...